机构：[1]Department of Hematology, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.内科片血液内科云南省第一人民医院[2]Kunming University of Science and Technology School of Medicine, Kunming, China.[3]Yunnan Blood Disease Hospital, The First People’s Hospital of Yunnan Province, Kunming, China.云南省第一人民医院[4]Yunnan Blood Disease Clinical Medical Center, The First People’s Hospital of Yunnan Province, Kunming, China云南省第一人民医院
BACKGROUND: A cure for the heterogeneous hematological malignancy multiple myeloma (MM) is yet to be developed. To date, the early risk factors associated with poor outcomes in MM have not been fully elucidated. Studies have shown an aberrant complement system in patients with MM, but the precise association necessitates elucidation. Therefore. this study scrutinizes the correlation between serum complement level and the disease outcome of patients with MM. METHODS: A retrospective analysis of 72 patients with MM (new diagnosis) with complement C4 and C3 along with common laboratory indicators was done. The Pearson chi(2) test and the Mann-Whitney U-test were done to evaluate categorical or binary variables and intergroup variance, respectively. Kaplan-Meier test and Cox proportional hazards regression were used for quantification of overall survival (OS) and unvariate or multivariate analyses, respectively. RESULTS: The Cox proportional hazard model analysis unveiled the following: platelet <= 115.5 x 10(9)/L (hazard ratio [HR] =5.82, 95% con- fidence interval [CI] =2.522-13.436, P< .001), complement C4 <= 0.095 g/L(HR =3.642. 95% CI = 1.486-8.924, P= .005), age years (HR =0.191. 95% CI =0.078-0.47, P<.001), and bone marrow plasma cell percentage >= 30.75% (HR =0.171, 95% CI =0.06-0.482, P= .001) can be used as independent predictors of OS. Of these. advanced age. low platelet level, and a high proportion of bone marrow plasma cells have been implicated in poor outcomes in patients with MM. Interestingly, a low complement 4 level can function as a new indicator of poor prognosis in patients with MM. CONCLUSION: Low levels of C4 are indicative of a poor outcome in newly diagnosed patients with MM.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81760028]; Training objects of medical subject leaders in Yunnan Province [D-2018017]; Open Project of Yunnan Blood Clinical Medical Center [2019LCZXKF-XY09, 2019LCZXKF-XY03,2021LCZXXF-XY09]
第一作者机构：[1]Department of Hematology, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.[2]Kunming University of Science and Technology School of Medicine, Kunming, China.[3]Yunnan Blood Disease Hospital, The First People’s Hospital of Yunnan Province, Kunming, China.[4]Yunnan Blood Disease Clinical Medical Center, The First People’s Hospital of Yunnan Province, Kunming, China
通讯作者：
通讯机构：[1]Department of Hematology, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.[2]Kunming University of Science and Technology School of Medicine, Kunming, China.[3]Yunnan Blood Disease Hospital, The First People’s Hospital of Yunnan Province, Kunming, China.[4]Yunnan Blood Disease Clinical Medical Center, The First People’s Hospital of Yunnan Province, Kunming, China[*1]Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, 157 Jinbi Road, Kunming 650032, China[*2]Yunnan Blood Disease Clinical Medical Center, Yunnan Blood Disease Hospital, National Key Clinical Specialty of Hematology, Department of Hematology, The First People’s Hospital of Yunnan Province, 157 Jinbi Road, Kunming 650032, China.
推荐引用方式(GB/T 7714)：
Zhang Lihua,Ling Xiaosui,Li Fan,et al.Complement 4 Aids in the Prediction of Newly Diagnosed Multiple Myeloma Outcome in Patients[J].CLINICAL MEDICINE INSIGHTS-ONCOLOGY.2022,16:doi:10.1177/11795549221079171.
APA：
Zhang, Lihua,Ling, Xiaosui,Li, Fan,Yang, Tonghua,Shi, Keqian...&He, Haiping.(2022).Complement 4 Aids in the Prediction of Newly Diagnosed Multiple Myeloma Outcome in Patients.CLINICAL MEDICINE INSIGHTS-ONCOLOGY,16,
MLA：
Zhang, Lihua,et al."Complement 4 Aids in the Prediction of Newly Diagnosed Multiple Myeloma Outcome in Patients".CLINICAL MEDICINE INSIGHTS-ONCOLOGY 16.(2022)
